Pawlik, Timothy M.
Tyler, Douglas S.
Sumer, Baran
Meric-Bernstam, Funda
Okereke, Ikenna C.
Beane, Joal D.
Dedhia, Priya H.
Ejaz, Aslam
McMasters, Kelly M.
Tanabe, Kenneth K.
Article History
Received: 23 April 2020
First Online: 29 May 2020
Disclosures
: Dr. Funda Meric-Bernstam reports receiving grant and financial support from Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co., in addition to consulting/advisory board relationships with Aduro BioTech Inc., DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd, Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, Zymeworks, Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, and Spectrum Pharmaceuticals. Timothy M. Pawlik, Douglas S. Tyler, Baran Sumer, Ikenna C. Okereke, Joal D. Beane, Priya H. Dedhia, Aslam Ejaz, Kelly M. McMasters, and Kenneth K. Tanabe have no conflicts to disclose.
Free to read: This content has been made available to all.